Advertisement

Optimizing the Ocular Surface for Regenerative Surgery: What Is Important and What Is Essential for the Outcome

  • Kai B. Kang
  • Ali R. D’jalilianEmail author
Chapter
Part of the Essentials in Ophthalmology book series (ESSENTIALS)

Abstract

The preoperative planning for regenerative surgery requires the optimization of patients’ ocular surface health. A dry and hostile surface environment will lead to failure of regenerative surgery. In this chapter, we outline several important approaches the surgeon should take to maximize the ocular surface health of patients. These approaches include optimization of the tear film, control of local and systemic inflammation, and repair of eyelid abnormalities.

Keywords

Ocular surface health Medical therapy Tear film Ocular surface inflammation Eyelid abnormalities 

Bibliography

  1. 1.
    Dry Eye WorkShop. Management and therapy of dry eye disease: report of the management and therapy subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5(2):163–78.CrossRefGoogle Scholar
  2. 2.
    Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea. 2007;26(3):260–4.  https://doi.org/10.1097/ICO.0b013e318033d79b.CrossRefPubMedGoogle Scholar
  3. 3.
    Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350–6.  https://doi.org/10.1016/j.ajo.2008.05.016.CrossRefPubMedGoogle Scholar
  4. 4.
    Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol. 2011;89(7):e591–7.  https://doi.org/10.1111/j.1755-3768.2011.02196.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology. 2017;124(1):43–52.  https://doi.org/10.1016/j.ophtha.2016.09.023.CrossRefPubMedGoogle Scholar
  6. 6.
    Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. 2016;35(9):1185–91.  https://doi.org/10.1097/ICO.0000000000000940.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Georgakopoulos CD, Makri OE, Pagoulatos D, et al. Effect of omega-3 fatty acids dietary supplementation on ocular surface and tear film in diabetic patients with dry eye. J Am Coll Nutr. 2017;36(1):38–43.  https://doi.org/10.1080/07315724.2016.1170643.CrossRefPubMedGoogle Scholar
  8. 8.
    Sheppard JD, Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea. 2013;32(10):1297–304.  https://doi.org/10.1097/ICO.0b013e318299549c.CrossRefPubMedGoogle Scholar
  9. 9.
    Thulasi P, Djalilian AR. Update in current diagnostics and therapeutics of dry eye disease. Ophthalmology. 2017;124(11S):S27–33.  https://doi.org/10.1016/j.ophtha.2017.07.022.CrossRefPubMedGoogle Scholar
  10. 10.
    Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32(1):44–53.  https://doi.org/10.1097/ICO.0b013e318254205f.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kashkouli MB, Fazel AJ, Kiavash V, Nojomi M, Ghiasian L. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. Br J Ophthalmol. 2015;99(2):199–204.  https://doi.org/10.1136/bjophthalmol-2014-305410.CrossRefPubMedGoogle Scholar
  12. 12.
    Liu Y, Kam WR, Ding J, Sullivan DA. Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation? Cornea. 2015;34(3):342–6.  https://doi.org/10.1097/ICO.0000000000000351.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27(Suppl 1):S25–30.  https://doi.org/10.1097/ICO.0b013e31817f3a0e.CrossRefPubMedGoogle Scholar
  14. 14.
    Hussain M, Shtein RM, Sugar A, et al. Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease. Cornea. 2014;33(12):1245–51.  https://doi.org/10.1097/ICO.0000000000000271.CrossRefPubMedGoogle Scholar
  15. 15.
    Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100(1):22–7.  https://doi.org/10.1136/bjophthalmol-2015-306842.CrossRefPubMedGoogle Scholar
  16. 16.
    La Porta Weber S, Becco de Souza R, Gomes JÁP, Hofling-Lima AL. The use of the esclera scleral contact lens in the treatment of moderate to severe dry eye disease. Am J Ophthalmol. 2016;163:167–173.e1.  https://doi.org/10.1016/j.ajo.2015.11.034.CrossRefPubMedGoogle Scholar
  17. 17.
    Alipour F, Kheirkhah A, Jabarvand BM. Use of mini scleral contact lenses in moderate to severe dry eye. Cont Lens Anterior Eye. 2012;35(6):272–6.  https://doi.org/10.1016/j.clae.2012.07.006.CrossRefPubMedGoogle Scholar
  18. 18.
    Carracedo G, Blanco MS, Martin-Gil A, Zicheng W, Alvarez JC, Pintor J. Short-term effect of scleral lens on the dry eye biomarkers in keratoconus. Optom Vis Sci. 2016;93(2):150–7.  https://doi.org/10.1097/OPX.0000000000000788.CrossRefPubMedGoogle Scholar
  19. 19.
    Harthan J, Nau CB, Barr J, et al. Scleral lens prescription and management practices: the SCOPE study. Eye Contact Lens. 2017.  https://doi.org/10.1097/ICL.0000000000000387.
  20. 20.
    Heur M, Bach D, Theophanous C, Chiu GB. Prosthetic replacement of the ocular surface ecosystem scleral lens therapy for patients with ocular symptoms of chronic Stevens-Johnson syndrome. Am J Ophthalmol. 2014;158(1):49–54.  https://doi.org/10.1016/j.ajo.2014.03.012.CrossRefPubMedGoogle Scholar
  21. 21.
    Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87(5):447–50.CrossRefGoogle Scholar
  22. 22.
    Schnyder CC, Tran VT, Mermoud A, Herbort CP. Sterile mucopurulent conjunctivitis associated with the use of dorzolamide eyedrops. Arch Ophthalmol. 1999;117(10):1429–31.PubMedGoogle Scholar
  23. 23.
    Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2):119–26.CrossRefGoogle Scholar
  24. 24.
    John T. Human amniotic membrane transplantation: past, present, and future. Ophthalmol Clin N Am. 2003;16(1):43–65, vi.CrossRefGoogle Scholar
  25. 25.
    Rahman I, Said DG, Maharajan VS, Dua HS. Amniotic membrane in ophthalmology: indications and limitations. Eye (Lond). 2009;23(10):1954–61.  https://doi.org/10.1038/eye.2008.410.CrossRefGoogle Scholar
  26. 26.
    Optimizing the ocular surface with amniotic membrane therapy|Ophthalmology Magazine. https://www.eyeworld.org/optimizing-ocular-surface-amniotic-membrane-therapy. Accessed 1 Jan 2018.
  27. 27.
    Paolin A, Cogliati E, Trojan D, et al. Amniotic membranes in ophthalmology: long term data on transplantation outcomes. Cell Tissue Bank. 2016;17(1):51–8.  https://doi.org/10.1007/s10561-015-9520-y.CrossRefPubMedGoogle Scholar
  28. 28.
    Vlasov A, Sia RK, Ryan DS, et al. Sutureless cryopreserved amniotic membrane graft and wound healing after photorefractive keratectomy. J Cataract Refract Surg. 2016;42(3):435–43.  https://doi.org/10.1016/j.jcrs.2015.11.045.CrossRefPubMedGoogle Scholar
  29. 29.
    Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106(4):811–6.  https://doi.org/10.1016/S0161-6420(99)90171-9.CrossRefPubMedGoogle Scholar
  30. 30.
    Hong S, Kim T, Chung S-H, Kim EK, Seo KY. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren’s syndrome. J Ocul Pharmacol Ther. 2007;23(1):78–82.  https://doi.org/10.1089/jop.2006.0091.CrossRefPubMedGoogle Scholar
  31. 31.
    Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–25.  https://doi.org/10.1016/j.jtos.2014.12.006.CrossRefPubMedGoogle Scholar
  32. 32.
    Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (Lond). 2017;4:7.  https://doi.org/10.1186/s40662-017-0072-z.CrossRefGoogle Scholar
  33. 33.
    Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60.  https://doi.org/10.1016/j.ophtha.2016.09.025.CrossRefPubMedGoogle Scholar
  34. 34.
    Vanrenterghem YF. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertens. 1999;8(6):669–74.CrossRefGoogle Scholar
  35. 35.
    Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236(4):429–36; discussion 436–437.  https://doi.org/10.1097/01.SLA.0000033429.89424.F8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Liang L, Sheha H, Tseng SCG. Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. Arch Ophthalmol. 2009;127(11):1428–34.  https://doi.org/10.1001/archophthalmol.2009.263.CrossRefPubMedGoogle Scholar
  37. 37.
    European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation. 1999;68(3):391–6.CrossRefGoogle Scholar
  38. 38.
    Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol. 2012;51:29–46.  https://doi.org/10.1159/000336185.CrossRefPubMedGoogle Scholar
  39. 39.
    Jordan DR, Anderson RL. The lateral tarsal strip revisited. The enhanced tarsal strip. Arch Ophthalmol. 1989;107(4):604–6.CrossRefGoogle Scholar
  40. 40.
    Reanimation of the paretic eyelid using gold weight implantation. A new approach and prospective evaluation. PubMed – NCBI. https://www.ncbi.nlm.nih.gov/pubmed/?term=gilbard+paretic+eyelid+god+weight. Accessed 31 Dec 2017.
  41. 41.
    Brown BZ, Beard C. Split-level full-thickness eyelid graft. Am J Ophthalmol. 1979;87(3):388–92.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of Illinois at Chicago, Department of Ophthalmology and Visual SciencesChicagoUSA

Personalised recommendations